A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
Public ClinicalTrials.gov record NCT06693843. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity (Body Mass Index ≥ 30 kg/m2) or Overweight (Body Mass Index ≥ 27 kg/m2) With at Least One Weight-related Comorbidity
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a randomized, double-blind, placebo-controlled, dose-range finding study of the efficacy, safety, tolerability, PK, and PD of multiple doses of aleniglipron in participants living with overweight or obesity with at least one weight-related comorbidity. Participants will be randomized to aleniglipron or placebo in a ratio of 3:1 within each Cohort receiving multiple-ascending, QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 36 weeks of treatment. At the end of the study (after completing 36 weeks of treatment), participants will be offered to continue with an open-label extension (OLE) where they will receive aleniglipron for an additional 36 weeks.
Study identification
- NCT ID
- NCT06693843
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 230 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 79 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 27, 2024
- Primary completion
- Oct 23, 2025
- Completion
- Jul 8, 2026
- Last update posted
- Aug 9, 2026
2024 – 2026
United States locations
- U.S. sites
- 39
- U.S. states
- 21
- U.S. cities
- 36
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ACCESS Research Site | Phoenix | Arizona | 85044 | — |
| ACCESS Research Site | Anaheim | California | 92801 | — |
| ACCESS Research Site | Los Angeles | California | 90057 | — |
| ACCESS Research Site | Montclair | California | 91763 | — |
| ACCESS Research Site | Rancho Cucamonga | California | 91730 | — |
| ACCESS Research Site | Sacramento | California | 95821 | — |
| ACCESS Research Site | Spring Valley | California | 91978 | — |
| ACCESS Research Site | Honolulu | Hawaii | 96814 | — |
| ACCESS Research Site | Chicago | Illinois | 60602 | — |
| ACCESS Research Site | Chicago | Illinois | 60637 | — |
| ACCESS Research Site | Evanston | Illinois | 60201 | — |
| ACCESS Research Site | Muncie | Indiana | 47304 | — |
| ACCESS Research Site | Valparaiso | Indiana | 46383 | — |
| ACCESS Research Site | West Des Moines | Iowa | 50265 | — |
| ACCESS Research Site | Baton Rouge | Louisiana | 70808 | — |
| ACCESS Research Site | Richfield | Minnesota | 55423 | — |
| ACCESS Research Site | City of Saint Peters | Missouri | 63303 | — |
| ACCESS Research Site | Hazelwood | Missouri | 63042 | — |
| ACCESS Research Site | Springfield | Missouri | 65807 | — |
| ACCESS Research Site | Albany | New York | 12203 | — |
| ACCESS Research Site | Binghamton | New York | 13905 | — |
| ACCESS Research Site | Brooklyn | New York | 10016 | — |
| ACCESS Research Site | Rochester | New York | 14609 | — |
| ACCESS Research Site | Wilmington | North Carolina | 28403 | — |
| ACCESS Research Site | Cincinnati | Ohio | 45219 | — |
| ACCESS Research Site | Norman | Oklahoma | 73069 | — |
| ACCESS Research Site | Medford | Oregon | 97504 | — |
| ACCESS Research Site | Pittsburgh | Pennsylvania | 15236 | — |
| ACCESS Research Site | Moncks Corner | South Carolina | 29461 | — |
| ACCESS Research Site | Chattanooga | Tennessee | 37421 | — |
| ACCESS Research Site | Austin | Texas | 78704 | — |
| ACCESS Research Site | Austin | Texas | 78731 | — |
| ACCESS Research Site | Dallas | Texas | 75226 | — |
| ACCESS Research Site | Dallas | Texas | 75243 | — |
| ACCESS Research Site | Mesquite | Texas | 75149 | — |
| ACCESS Research Site | Shavano Park | Texas | 78231 | — |
| ACCESS Research Site | West Jordan | Utah | 84088 | — |
| ACCESS Research Site | Winchester | Virginia | 22601 | — |
| ACCESS Research Site | Morgantown | West Virginia | 26505 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06693843, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 9, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06693843 live on ClinicalTrials.gov.